Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones
20 déc. 2018 08h00 HE
|
Pascal Biosciences Inc.
- 2018 pipeline expansion includes lead cannabinoid-based cancer therapeutic- Clinical trial in glioblastoma to begin in 2019 VANCOUVER, British Columbia and SEATTLE, Dec. 20, 2018 (GLOBE NEWSWIRE)...
Pascal Biosciences Announces Year-End Investor Update Webcast
10 déc. 2018 20h45 HE
|
Pascal Biosciences Inc.
Advancement of Cannabinoid Cancer Programs and Corporate Review to be Presented Scheduled for Dec. 17, 2018 at 1:30 p.m. Pacific VANCOUVER, British Columbia and SEATTLE, Dec. 10, 2018 (GLOBE...
Pascal Biosciences Expands Leadership Team to Support Strategic Advancement of Its Cannabinoid Based Programs
28 nov. 2018 08h00 HE
|
Pascal Biosciences Inc.
VANCOUVER, B.C. and SEATTLE, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the...
Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells
05 nov. 2018 08h00 HE
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia and SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced...
Pascal Biosciences and the University of Washington Enter Into Exclusive License Agreement to Develop Cannabinoid-based Medicine for Cancer
30 oct. 2018 08h00 HE
|
Pascal Biosciences Inc.
Program Developed in Lab of Renowned Cannabis Researcher Dr. Nephi Stella-Lead Candidate for Glioblastoma to Begin Clinical Testing in 2019 VANCOUVER, B.C. and SEATTLE, Oct. 30, 2018 (GLOBE...
Pascal Biosciences appoints Julie M. Eastland, accomplished financial executive, to Board of Directors
16 juil. 2018 09h00 HE
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the...
Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration
18 juin 2018 08h30 HE
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX-V:PAS) (Pascal), is pleased to announce significant progress in its cannabinoid based research and...
Pascal Announces Oversubscription of Financing
08 mars 2018 20h35 HE
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia, March 08, 2018 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Pascal...
Pascal Biosciences Inc. Announces Non-Brokered Private Placement
23 févr. 2018 11h14 HE
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) arranges a non-brokered private placement of up to 12,500,000 units...
Pascal Biosciences Identifies Molecules in Cannabis That Stimulate the Immune System to Destroy Tumor Cells
21 févr. 2018 09h30 HE
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia and SEATTLE, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today announced the Company has discovered certain...